



SXH
#2
2-8-93

Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

91311761.0



Den Haag, den
The Hague, 16/11/92
La Haye, le

I.L.C. Hatten-Heckman

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation



Anmeldung Nr.: 91311761.0
Application no.:
Demande n°:

Anmeldetag: 18/12/91
Date of filing:
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
AKTIEBOLAGET ASTRA
S-151 85 Södertälje
SWEDEN

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention: New combination of formoterol and budesonide

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
A61K31/57, // (A61K31/57, 31:165)

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/DE/DK/ES/FR/GB/GR/IT/LI/LU/MC/NL/SE
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks: The original title of the invention reads as follows: "New combination"
Remarques:

NEW COMBINATION

Field of the invention

This invention relates to improvements in the treatment of mild as well as severe asthma and other
5 respiratory disorders. More particularly, it relates to the use of a bronchodilator in combination with a steroidal anti-inflammatory drug for the treatment of respiratory disorders such as asthma, and to pharmaceutical compositions containing the two active ingredients. It
10 emphasizes the use of a long-acting bronchodilator which provides rapid relief of symptoms.

Background of the invention

There have recently been significant advances in our understanding of asthma. Despite many advances, both
15 in awareness of the disease by doctors and patients alike, coupled with the introduction of very powerful and effective anti-asthma drugs, asthma remains a poorly understood and often poorly treated disease. Previously, contraction of airway smooth muscles has been regarded as
20 the most important feature of asthma. Recently there has been a marked change in the way asthma is managed, stemming from the fact that asthma is recognized as a chronic inflammatory disease. Uncontrolled airway inflammation may lead to mucosal damage and structural changes giving
25 irreversible narrowing of the airways and fibrosis of the lung tissue. Therapy should therefore be aimed at controlling symptoms so that normal life is possible and at the same time provide basis for treating the underlying inflammation.

30 The most common cause for poor control of asthma is poor compliance with the long-term management of chronic

asthma, particularly with prophylactic treatments, such as inhaled steroids, which do not give immediate symptom relief. Patients will readily take β_2 -agonist inhalers, since these provide rapid relief of symptoms, but often do not take prophylactic therapy, such as inhaled steroids, regularly because there is no immediate symptomatic benefit. They also counteract down regulation of β_2 -adrenoceptor agonists.

Formoterol, (N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide), is an adrenoceptor agonist which selectively stimulates β_2 -receptors, thus producing relaxation of bronchial smooth muscle, inhibition of the release of endogenous spasmogens, inhibition of oedema caused by endogenous mediators, and increased mucociliary clearance. Inhaled formoterol fumarate acts rapidly, usually within minutes and exerts a prolonged bronchodilation, which in clinical trials has been demonstrated as up to 12 hours.

Budesonide, (16,17-butyridenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione), may be given in a high inhaled dose (up to 2 mg daily) with very low systemic effects, possibly because of its rapid metabolism. The high rapid systemic elimination of budesonide is due to extensive and rapid hepatic metabolism. Long term clinical studies have shown that inhaled budesonide is a pharmacologically safe drug. High doses of inhaled budesonide are highly effective and well tolerated when used in oral steroid replacement therapy. Budesonide represents a logical, safe and effective therapy for long term control of asthma.

The inhaled route of administration enables the dose to be delivered directly to the airways. By this type of administration, it is possible to give a small dose and thereby minimizing unwanted side-effects. The drawbacks of the currently available bronchodilators are their

relatively short duration of action. By using a compound with long duration e.g. formoterol it would be possible to avoid the nocturnal asthma, which so often causes considerable anxiety and debility to the patients.

- 5 Formoterol gives less nocturnal waking than the commonly used short-acting agonists like salbutamol, terbutaline and the like. Formoterol has been registered for oral administration in Japan since 1986.

- Earlier mentioned combinations of long-acting β_2 -
10 agonists and steroids include the use of salmeterol and beclomethasone dipropionate (European Patent Application EP 416 950, Glaxo) and salmeterol and fluticasone propionate (European Patent Application EP 416 951, Glaxo). However
15 these combinations suffer a number of disadvantages with regard to the desire for a rapid relief of symptoms and treating mild as well as severe asthma and other respiratory disorders.

Outline of the Invention

- The present invention is based on the concept of a
20 novel combination therapy whereby formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or separately by inhalation. This combination has not only a greater efficiency and duration of bronchodilator action
25 but the combination also has a rapid onset of action. This new feature is of utmost importance in order to establish a higher compliance for patients and it provides a rescue medicine thereby avoiding the necessity for the patient of carrying two different inhalers. This simplifies life for
30 patients considerably and makes life more comfortable and secure. The combination permits a twice daily dosing regime as a basic treatment of asthma, particularly nocturnal asthma.

The present invention provides a medicament containing, separately, or together, (i) formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and (ii) budesonide for simultaneous, sequential or
5 separate administration by inhalation in the treatment of respiratory disorder.

The invention also provides a pharmaceutical composition for administration by inhalation in the treatment of respiratory disorder which composition
10 comprises formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide.

According to another aspect of the invention there are provided pharmaceutical compositions comprising effective amounts of formoterol (and/or a physiologically
15 acceptable salt and/or solvate thereof) and budesonide as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.

The invention further provides formoterol (and/or a
20 physiologically acceptable salt and/or solvate thereof) and budesonide for use in combination therapy by simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.

Further the invention provides the use of
25 formoterol (and/or a physiologically acceptable salt and/or solvate thereof) in the manufacture of a medicament for combination therapy where formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or
30 separately by inhalation in the treatment of respiratory disorder and the use of budesonide in the manufacture of a medicament for combination therapy where formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously,
35 sequentially or separately by inhalation in the treatment

of respiratory disorder.

The invention additionally relates to the use of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide in the manufacture of a medicament for combination therapy for simultaneous, sequential or separate administration of formoterol and budesonide by inhalation in the treatment of respiratory disorder.

According to a further feature of the invention there is provided a method of treating respiratory disorder which comprises the simultaneous, sequential or separate administration by inhalation of effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide.

Suitable physiologically salts of formoterol include acid addition salts derived from inorganic and organic acids, such as the hydrochloride, hydrobromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate, acetate, succinate, lactate, glutarate, gluconate, tricarballoylate, hydroxynaphthalene-carboxylate or oleate. Formoterol is preferably used in the form of its fumarate salt and as a dihydrate.

The ratio of formoterol to budesonide used according to the invention is preferably within the range of 1:4 to 1:70. The two drugs may be administered separately in the same ratio.

The intended dose regimen is a twice daily administration, where the suitable daily dose of formoterol is in the range of 6 to 100 μg with a preferred dose of 6-48 μg and the suitable daily dose for budesonide is 50 to 4800 μg with a preferred dose of 100-1600 μg . The particular dose used will strongly depend on the patient (age, weight etc) and the severity of the disease (mild,

moderate, severe asthma etc).

For administration, the combination is suitably inhaled from a nebulizer, from a pressurized metered dose inhaler or as a dry powder from a dry powder inhaler (e.g. as sold under the trade mark Turbuhaler) or from a dry powder inhaler utilizing gelatine, plastic or other capsules, cartridges or blister packs.

A diluent or carrier, generally non-toxic and chemically inert to the medicament e.g. lactose, dextran, mannitol or glucose or any additives that will give the medicament a desired taste, can be added to the powdered medicament.

Examples of the preparation of suitable dosage forms according to the invention include the following:

Formoterol fumarate dihydrate and budesonide (optionally premicronized) are mixed in the proportions given above. The agglomerated, free-flowing micronized mixture may be filled into dry powder inhaler such as sold under the trade mark Turbuhaler. When a capsule system issued, it is desirable to include a filler in the mixture.

The micronized mixture may be suspended or dissolved in a liquid propellant mixture which is kept in a container that is sealed with a metering valve and fitted into a plastic actuator. The propellants used may be chlorofluorocarbons of different chemical formulae. The most frequently used chlorofluorocarbon propellants are trichloromonofluoromethane (propellant 11), dichlorodifluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 114), tetrafluoroethane (propellant 134a) and 1,1-difluoro-ethane (propellant 152a). Low concentrations of a surfactant such as sorbitan trioleate, lecithin, disodium dioctylsulphosuccinate or oleic acid may also be used to improve the physical stability.

The invention is further illustrated by way of example with reference to the following Examples.

Example 1 - Dry Powder Inhaler (Turbuhaler)

| <u>Active ingredient</u> | <u>Per dose</u> |
|------------------------------------|-----------------|
| Formoterol (as fumarate dihydrate) | 12 µg |
| Budesonide | 200 µg |

- 5 The storage unit of the inhaler is filled with sufficient for at least 200 doses.

| <u>Active ingredient</u> | <u>Per dose</u> |
|------------------------------------|-----------------|
| Formoterol (as fumarate dihydrate) | 24 µg |
| Budesonide | 200 µg |

- 10 The storage unit is filled with sufficient for at least 200 doses.

| <u>Active ingredient</u> | <u>Per dose</u> |
|------------------------------------|-----------------|
| Formoterol (as fumarate dihydrate) | 12 µg |
| Budesonide | 100 µg |

- 15 The storage unit is filled with sufficient for at least 200 doses.

Example 2 - Metered dose inhaler

| | <u>Active ingredient</u> | <u>Per dose</u> |
|----|------------------------------------|-----------------|
| | Formoterol (as fumarate dihydrate) | 12 µg |
| 20 | Budesonide | 200 µg |
| | Stabilizer | 0.1 - 0.7 mg |
| | Propellant | 25 - 100 µl |

| | <u>Active ingredient</u> | <u>Per dose</u> |
|----|------------------------------------|-----------------|
| | Formoterol (as fumarate dihydrate) | 24 µg |
| 25 | Budesonide | 200 µg |
| | Stabilizer | 0.1 - 0.7 mg |
| | Propellant | 25 - 100 µl |

| | <u>Active ingredient</u> | <u>Per dose</u> |
|---|------------------------------------|-----------------|
| | Formoterol (as fumarate dihydrate) | 12 µg |
| | Budesonide | 200 µg |
| | Stabilizer | 0.1 - 0.7 mg |
| 5 | Propellant | 25 - 100 µl |

Example 3 - Metered dose dry powder formulation

| | <u>Active ingredient</u> | <u>Per dose</u> |
|----|------------------------------------|------------------------|
| | Formoterol (as fumarate dihydrate) | 12 µg |
| | Budesonide | 200 µg |
| 10 | Lactose | up to 5, 12.5 or 25 mg |

| | <u>Active ingredient</u> | <u>Per dose</u> |
|--|------------------------------------|------------------------|
| | Formoterol (as fumarate dihydrate) | 24 µg |
| | Budesonide | 200 µg |
| | Lactose | up to 5, 12.5 or 25 mg |

| | | |
|----|------------------------------------|------------------------|
| 15 | <u>Active ingredient</u> | <u>Per dose</u> |
| | Formoterol (as fumarate dihydrate) | 12 µg |
| | Budesonide | 100 µg |
| | Lactose | up to 5, 12.5 or 25 mg |

CLAIMS

4

1. A medicament containing, separately or together, (i) formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and (ii) budesonide
5 for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.

2. A pharmaceutical composition for administration by inhalation in the treatment of respiratory disorder which composition comprises formoterol
10 (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide.

3. A pharmaceutical composition comprising effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide as a
15 combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.

4. Formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide for
20 use in combination therapy by simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.

5. The use of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) in
25 the manufacture of a medicament for combination therapy where formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or separately by inhalation in the treatment of respiratory disorder.

30 6. The use of budesonide in the manufacture of a medicament for combination therapy where formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or separately by inhalation in the treatment

of respiratory disorder.

7. The use of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide in the manufacture of a medicament for
- 5 combination therapy for simultaneous, sequential or separate administration of formoterol and budesonide by inhalation in the treatment of respiratory disorder.

ABSTRACT

NEW COMBINATION

Effective amounts of formoterol (and/or a
physiologically acceptable salt and/or solvate thereof) and
5 budesonide are used in combination for simultaneous,
sequential or separate administration by inhalation in the
treatment of respiratory disorder.